Highlights in Multiple Myeloma from the Annual ASCO and EHA 2022 Meetings
Please Log In or Register to continue.
Release Date: August 08, 2022
Expiration Date: August 08, 2023
Expected time to complete this activity as designed: 15 minutes
There are no fees for participating in or receiving credit for this online activity.
Program Overview
Join Dr. Richter as he reviews new and noteworthy data on newly diagnosed and relapsed/refractory multiple myeloma from the American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) 2022 annual meetings.
Target Audience
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurse practitioners, pharmacists and other allied healthcare professionals who provide care to patients with multiple myeloma.
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Identify novel approaches to the management of newly diagnosed and relapsed/refractory multiple myeloma
Agenda
Highlights in Multiple Myeloma from the Annual ASCO and EHA 2022 Meetings – Joshua Richter, MD
Instructions for Participation and Credit
This activity is eligible for credit through August 08, 2023. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Faculty Biography
Joshua Richter, MD
Assistant Professor of Medicine
Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
Director of Myeloma
Blavatnik Family Center at Chelsea Mount Sinai
New York, New York
Dr. Joshua Richter received his medical degree from New York Medical College. He completed an internal medicine residency at St. Vincent’s Hospital – New York Medical College, and a hematology/oncology fellowship at Yale Cancer Center, Yale University. Dr. Richter served as Clinical Assistant Professor at Rutgers University, New Brunswick, New Jersey, and worked in the Division of Myeloma at the John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey. He is currently an Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai and Director of Myeloma at Blavatnik Family Center at Chelsea Mount Sinai.
Dr. Richter is board certified in internal medicine, hematology, and medical oncology. He has been published in numerous oncology journals including New England Journal of Medicine, Blood, Journal of Clinical Oncology, and the British Journal of Haematology. Dr. Richter specializes in multiple myeloma as well as other plasma cell dyscrasias such as amyloidosis and Waldenstrom’s macroglobulinemia. His clinical research interests focus on multi-functional antibodies and precision medicine.
Accreditation
CME CREDIT MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. |
|
CPE CREDIT MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.25 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-22-008-H01-P. Knowledge-based CPE activity. In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program. International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406. |
|
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards. |
Disclosure
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.
Faculty Disclosures
Dr. Joshua Richter has relevant financial relationships related to advisory activities from Adaptive Biotechnologies, AstraZeneca, Celgene Corporation - A Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc., Karyopharm Therapeutics, Oncopeptides, AB, Sanofi, Secura Bio, Inc., and X4 Pharmaceuticals, Inc., and as a consultant from Celgene Corporation - A Bristol-Myers Squibb Company, Oncopeptides and Takeda Oncology. He is on the speakers’ bureau for Adaptive Biotechnologies, Janssen, and Sanofi.
All of the relevant financial relationships listed for this individual have been mitigated.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.
Planning Committee
Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, Lilian McVey, Medical Writer, and Andrea Mathis, Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
Peer Reviewer
Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at [email protected]
Provided by MediCom Worldwide, Inc.
This activity is not commercially supported.
©2022 MediCom Worldwide, Inc., 660 Newtown Yardley Rd, Suite 203 · Newtown, PA 18940, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.